Role of polymorphic adhesion molecules in the development of graft-versus-leukemia effect after HLA-matched allogeneic stem cell transplantation

DOI Web Site PubMed 15 References
  • SHIOBARA Shintaro
    Division of Transfusion Medicine, Kanazawa University Hospital
  • SATO Hidehiro
    Division of Transfusion Medicine, Kanazawa University Hospital
  • FURUKAWA Tastuo
    Division of Bone Marrow Transplantation, Niigata University Medical and Dental Hospital
  • TSUKADA Jyunichi
    First Department of Internal Medicine, University of Occupational and Environment Health
  • YASUE Shizuka
    Division of Transfusion Medicine, Kanazawa University Hospital
  • TAKEDA Hiroko
    Medical Laboratory Division, Niigata University Medical and Dental Hospital
  • TOGAWA Akiko
    Faculty of Health Science, Kanazawa University School of Medicine
  • TAIRA Masumi
    Faculty of Health Science, Kanazawa University School of Medicine
  • SAKAI Yoshiko
    Faculty of Health Science, Kanazawa University School of Medicine
  • AIZAWA Yoshifusa
    Division of Hematology, Niigata University Graduate School of Medical and Dental Science
  • NAKAO Shinnji
    Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science

Bibliographic Information

Other Title
  • HLA適合同種造血幹細胞移植後のGVL効果における多型接着分子の役割
  • 臨床研究 HLA適合同種造血幹細胞移植後のGVL効果における多型接着分子の役割
  • リンショウ ケンキュウ HLA テキゴウ ドウシュ ゾウケツ カンサイボウ イショク ゴ ノ GVL コウカ ニ オケル タケイ セッチャク ブンシ ノ ヤクワリ

Search this article

Abstract

Mismatches of minor histocompatibility antigens (mHas) between HLA-identical stem cell donors and recipients are known as a major risk factor for graft-versus-host disease (GVHD). We determined the alleles of 5 polymorphic molecules including HA-1 and 4 adhesion molecules in 102 patients who had undergone stem cell transplantation from HLA-identical donors and investigated the association of their mismatches with the relapse rate and incidence of GVHD. We observed relapse rates of 16.1% in patients with at least one or more incompatibilities and 39.4% in patients without incompatibilities (p=0.018). The respective relapse rates of patients with CD62L, HA-1, CD31 exon 563, CD31 exon 125 and 49b incompatibilities were 6.1%, 14.3%, 11.7%, 20% and 40%. Only patients with CD62L incompatibilities showed a lower relapse rate than patients who received a compatible graft. Since there was no difference between patients with and without incompatibilities as far as the appearance of acute GVHD (≥2) was concerned, we conclude that the polymorphic CD62L molecule contributes to graft-versus-leukemia rather than the development of GVHD after HLA-identical stem cell transplantation.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 45 (7), 518-523, 2004

    The Japanese Society of Hematology

References(15)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top